Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

COVID-19 and lung cancer: What do we know?

Serrano et al., Ann. Oncol., 2020, Sep, 31, S1026, doi:10.1016/j.annonc.2020.08.1830
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 43% Improvement Relative Risk HCQ for COVID-19  Serrano et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 22 patients in Spain Lower mortality with HCQ (not stat. sig., p=0.15) c19hcq.org Serrano et al., Ann. Oncol., 2020, Sep.., Sep 2020 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19hcq.org
Small retrospective study of 22 lung cancer patients, 14 treated with HCQ+AZ, showing HCQ+AZ mortality relative risk RR 0.57, p = 0.145.
risk of death, 43.0% lower, RR 0.57, p = 0.14, treatment 6 of 14 (42.9%), control 6 of 8 (75.0%), NNT 3.1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Serrano et al., 22 Sep 2020, retrospective, Spain, peer-reviewed, 8 authors.
This PaperHCQAll
Developing a risk assessment score for cancer patients during the COVID-19 pandemic
A Indini, M Cattaneo, M Ghidini, E Rijavec, C Bareggi, B Galassi, D Gambini, F Grossi
Background: Data on the novel coronavirus (CoV) respiratory disease in cancer patients (pts) are limited. In some individuals, CoV infection triggers an aberrant inflammatory response, leading to lung tissue damage. Cancer pts treated with immunotherapy (IT) may therefore be more at risk for COVID-19 infection and related complications. Methods: We performed a thorough review of the literature on CoV pathogenesis and cancer, selecting shared features of the two disease entities to develop a riskassessment score to quantify both the risk of infection and the risk implied in cancer treatment delays. Results: The score includes clinical and laboratory variables (Table ) . Pts' characteristics include: age, presence of comorbidities (hypertension, cardiovascular disease, diabetes, chronic obstructive pulmonary disease, chronic systemic infections), obesity, sex, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and concomitant steroid treatment (>10 mg daily of prednisone equivalent, lasting for >1-month period). Disease characteristics include: lung cancer diagnosis, history of thoracic radiotherapy (RT) (only for pts with extra-thoracic tumours). Treatment characteristics include: line of treatment, type (IT or combined IT/chemotherapy [CT] considered high-risk, followed by CT, and other anticancer drugs), history of immunerelated adverse events (irAEs). Laboratory tests include: levels of neutrophil-to-lymphocite ratio (NLR), lactate-dehydrogenase (LDH), and C-reactive protein (CRP). Based on the resulting score, pts can be divided in the following categories of risk: low (score <4), intermediate (score 4-6), and high risk (score >7). Conclusions: There is a strong rationale supporting the presented data as potential risk factors for COVID-19 in cancer pts. The present score is currently undergoing validation on a wide population of cancer pts to confirm its role and potentially help physicians' treatment decisions. Legal entity responsible for the study: The authors.
{ 'indexed': { 'date-parts': [[2023, 10, 12]], 'date-time': '2023-10-12T13:55:49Z', 'timestamp': 1697118949819}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 9, 1]], 'date-time': '2020-09-01T00:00:00Z', 'timestamp': 1598918400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2021, 9, 1]], 'date-time': '2021-09-01T00:00:00Z', 'timestamp': 1630454400000}, 'content-version': 'vor', 'delay-in-days': 365, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1016/j.annonc.2020.08.1830', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 22]], 'date-time': '2020-09-22T09:08:35Z', 'timestamp': 1600765715000}, 'page': 'S1026', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': '1766P COVID-19 and lung cancer: What do we know?', 'prefix': '10.1016', 'volume': '31', 'author': [ {'given': 'G.', 'family': 'Serrano', 'sequence': 'first', 'affiliation': []}, {'given': 'J.', 'family': 'Rogado', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Pangua', 'sequence': 'additional', 'affiliation': []}, {'given': 'B.', 'family': 'Obispo', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Martin Marino', 'sequence': 'additional', 'affiliation': []}, {'given': 'M.', 'family': 'Perez-Perez', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Lopez-Alfonso', 'sequence': 'additional', 'affiliation': []}, {'given': 'M.A.', 'family': 'Lara', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': 'Annals of Oncology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420418265?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0923753420418265?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 11, 1]], 'date-time': '2021-11-01T18:59:59Z', 'timestamp': 1635793199000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0923753420418265'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 0, 'alternative-id': ['S0923753420418265'], 'URL': 'http://dx.doi.org/10.1016/j.annonc.2020.08.1830', 'relation': {}, 'ISSN': ['0923-7534'], 'subject': ['Oncology', 'Hematology'], 'container-title-short': 'Annals of Oncology', 'published': {'date-parts': [[2020, 9]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit